Enteric neuroplasticity and dysmotility in inflammatory disease: key players and possible therapeutic targets

被引:24
|
作者
Spear, Estelle T. [1 ]
Mawe, Gary M. [2 ]
机构
[1] Stanford Univ, Dept Med, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA
[2] Univ Vermont, Dept Neurol Sci, Burlington, VT 05405 USA
关键词
autoantibody; enteric nervous system; gastrointestinal motility; glia; macrophage; PURINERGIC NEUROMUSCULAR-TRANSMISSION; SULFONIC-ACID COLITIS; MYENTERIC AH NEURONS; SEROTONIN TRANSPORTER; FUNCTIONAL AUTOANTIBODY; RECEPTOR AUTOANTIBODIES; ENHANCED EXCITABILITY; POSTOPERATIVE ILEUS; OXIDATIVE STRESS; GLIAL-CELLS;
D O I
10.1152/ajpgi.00206.2019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Intestinal functions, including motility and secretion, are locally controlled by enteric neural networks housed within the wall of the gut. The fidelity of these functions depends on the precision of intercellular signaling among cellular elements, including enteric neurons, epithelial cells, immune cells, and glia, all of which are vulnerable to disruptive influences during inflammatory events. This review article describes current knowledge regarding inflammation-induced neuroplasticity along key elements of enteric neural circuits, what is known about the causes of these changes, and possible therapeutic targets for protecting and/or repairing the integrity of intrinsic enteric neurotransmission. Changes that have been detected in response to inflammation include increased epithelial serotonin availability, hyperexcitability of intrinsic primary afferent neurons, facilitation of synaptic activity among enteric neurons, and attenuated purinergic neuromuscular transmission. Dysfunctional propulsive motility has been detected in models of colitis, where causes include the changes described above, and in models of multiple sclerosis and other autoimmune conditions, where autoantibodies are thought to mediate dysmotility. Other cells implicated in inflammation-induced neuroplasticity include muscularis macrophages and enteric glia. Targeted treatments that are discussed include 5-hydroxytryptamine receptor 4 agonists, cyclooxygenase inhibitors, antioxidants, B cell depletion therapy, and activation of anti-inflammatory pathways.
引用
收藏
页码:G853 / G861
页数:9
相关论文
共 50 条
  • [1] Pericytes in Alzheimer's disease: Key players and therapeutic targets
    Zhang, Yu
    Mu, Ben-Rong
    Ran, Zhao
    Zhu, Tao
    Huang, Xin
    Yang, Xiong
    Wang, Dong-Mei
    Ma, Quan-Hong
    Lu, Mei-Hong
    [J]. EXPERIMENTAL NEUROLOGY, 2024, 379
  • [2] Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
    Ramji, Dipak P.
    Davies, Thomas S.
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2015, 26 (06) : 673 - 685
  • [3] MicroRNAs: Key players in carcinogenesis and novel therapeutic targets
    Mirnezami, A. H. F.
    Pickard, K.
    Zhang, L.
    Primrose, J. N.
    Packham, G.
    [J]. EJSO, 2009, 35 (04): : 339 - 347
  • [4] Neuraminidases-Key Players in the Inflammatory Response after Pathophysiological Cardiac Stress and Potential New Therapeutic Targets in Cardiac Disease
    Heimerl, Maren
    Gausepohl, Thomas
    Mueller, Julia H.
    Ricke-Hoch, Melanie
    [J]. BIOLOGY-BASEL, 2022, 11 (08):
  • [5] Therapeutic targets in inflammatory disease
    Hume, DA
    Fairlie, DP
    [J]. CURRENT MEDICINAL CHEMISTRY, 2005, 12 (25) : 2925 - 2929
  • [6] SELECTINS AS THERAPEUTIC TARGETS FOR INFLAMMATORY DISEASE
    PAULSON, JC
    PHILLIPS, ML
    ETZIONI, A
    ASAKO, H
    GRANGER, DN
    HARLAN, JM
    MULLIGAN, MS
    WARD, PA
    WINN, RK
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 327 - 327
  • [7] Therapeutic targets in inflammatory bowel disease
    Fluxa, Daniela
    Abreu, Maria T.
    [J]. REVISTA MEDICA CLINICA LAS CONDES, 2019, 30 (04): : 315 - 322
  • [8] SELECTINS AS THERAPEUTIC TARGETS FOR INFLAMMATORY DISEASE
    PAULSON, JC
    PHILLIPS, ML
    ETZIONI, A
    ASAKO, H
    GRANGER, DN
    HARLAN, JM
    MULLIGAN, MS
    WARD, PA
    WINN, RK
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 364 - 364
  • [9] miRNAs as Therapeutic Targets in Inflammatory Disease
    Lu, Qianjin
    Wu, Ruifang
    Zhao, Ming
    Garcia-Gomez, Antonio
    Ballestar, Esteban
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2019, 40 (11) : 853 - 865
  • [10] Therapeutic targets in inflammatory bowel disease
    Di Sabatino, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52